Journal of International Oncology ›› 2023, Vol. 50 ›› Issue (1): 12-16.doi: 10.3760/cma.j.cn371439-20220805-00002
• Original Articles • Previous Articles Next Articles
Che Yanmin, Zhang Wanhong(), Lyu Gaofeng
Received:
2022-08-05
Revised:
2022-11-15
Online:
2023-01-08
Published:
2023-03-16
Contact:
Zhang Wanhong
E-mail:164266869@qq.com
Che Yanmin, Zhang Wanhong, Lyu Gaofeng. Clinical prognosis and influencing factors of patients with hypopharyngeal squamous cell carcinoma treated by salvage surgery[J]. Journal of International Oncology, 2023, 50(1): 12-16.
"
指标 | 例数 | 术后5年死亡人数(例) | 术后5年死亡比例(%) | χ2值 | P值 |
---|---|---|---|---|---|
挽救手术年龄(岁) | |||||
<60 | 40 | 0 | 0 | 30.25 | <0.001 |
≥60 | 38 | 21 | 55.26 | ||
性别 | |||||
男性 | 73 | 20 | 27.40 | <0.01 | >0.999 |
女性 | 5 | 1 | 20.00 | ||
初治治疗方案 | |||||
手术+辅助放疗 | 42 | 10 | 23.81 | 0.45 | 0.503 |
根治性放疗 | 36 | 11 | 30.56 | ||
再发方式 | |||||
残留 | 33 | 12 | 36.36 | 2.59 | 0.107 |
复发 | 45 | 9 | 20.00 | ||
再发肿瘤位置 | |||||
肿瘤局部 | 50 | 19 | 38.00 | ||
淋巴结 | 17 | 1 | 5.88 | 8.72 | 0.013 |
造瘘口 | 11 | 1 | 9.09 | ||
再发肿瘤最大径(cm) | |||||
<3 | 25 | 8 | 32.00 | 0.48 | 0.488 |
≥3 | 53 | 13 | 24.53 | ||
挽救手术切缘状态 | |||||
阳性 | 60 | 21 | 35.00 | 6.93 | 0.008 |
阴性 | 18 | 0 | 0 | ||
挽救手术方式 | |||||
单纯局部切除 | 30 | 8 | 26.67 | 1.36 | 0.714 |
局部切除+颈部淋巴 结清扫 | 20 | 4 | 20.00 | ||
单纯根治性淋巴清扫 | 18 | 5 | 27.78 | ||
造瘘口复发癌切除 | 10 | 4 | 40.00 | ||
挽救手术后接受辅助 放(化)疗 | |||||
是 | 30 | 12 | 40.00 | 4.24 | 0.040 |
否 | 48 | 9 | 18.75 | ||
再发肿瘤分化程度 | |||||
低分化 | 22 | 8 | 36.36 | 1.39 | 0.239 |
中分化 | 56 | 13 | 23.21 | ||
再发肿瘤浸润深度 | |||||
黏膜、黏膜下层或淋 巴结包膜未侵犯 | 25 | 12 | 48.00 | 8.31 | 0.004 |
肌肉、骨组织或淋巴 结包膜侵犯 | 53 | 9 | 16.98 | ||
术后并发症 | |||||
无 | 61 | 15 | 24.59 | 0.33 | 0.568 |
有 | 17 | 6 | 35.29 |
"
相关因素 | β值 | 标准误 | Wald χ2值 | P值 | OR值(95%CI) |
---|---|---|---|---|---|
挽救手术年龄(<60岁为对照) | 1.254 | 1.089 | 1.33 | 0.249 | 3.50(0.41~29.62) |
再发肿瘤位置 | - | - | - | - | - |
手术切缘状态(造瘘口为对照) | 1.025 | 0.872 | 1.38 | 0.239 | 2.79(0.50~15.40) |
淋巴结(造瘘口为对照) | 1.253 | 0.943 | 1.77 | 0.183 | 3.50(0.55~22.23) |
手术切缘状态(阴性为对照) | 3.268 | 0.891 | 13.45 | <0.001 | 26.26(4.58~150.62) |
肿瘤浸润深度(肌肉、骨组织或淋巴结包膜侵犯为对照) | 2.641 | 0.780 | 11.46 | <0.001 | 14.03(3.04~64.70) |
挽救手术后是否接受放(化)疗(否为对照) | 2.045 | 0.778 | 6.90 | 0.008 | 7.73(1.68~35.54) |
[1] |
Mody MD, Rocco JW, Yom SS, et al. Head and neck cancer[J]. Lancet, 2021, 398(10318): 2289-2299. DOI: 10.1016/S0140-6736(21)01550-6.
doi: 10.1016/S0140-6736(21)01550-6 pmid: 34562395 |
[2] |
Pujo K, Philouze P, Scalabre A, et al. Salvage surgery for recurrence of laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study from 2005 to 2013[J]. Eur Ann Otorhinolaryngol Head Neck Dis, 2018, 135(2): 111-117. DOI: 10.1016/j.anorl.2017.11.001.
doi: S1879-7296(17)30176-X pmid: 29198646 |
[3] |
Chun SJ, Keam B, Heo DS, et al. Optimal timing for salvage surgery after definitive radiotherapy in hypopharyngeal cancer[J]. Radiat Oncol J, 2018, 36(3): 192-199. DOI: 10.3857/roj.2018.00311.
doi: 10.3857/roj.2018.00311 |
[4] |
Kim YH, Roh JL, Choi SH, et al. Prediction of pharyngocutaneous fistula and survival after salvage laryngectomy for laryngohypopharyngeal carcinoma[J]. Head Neck, 2019, 41(9): 3002-3008. DOI: 10.1002/hed.25786.
doi: 10.1002/hed.25786 |
[5] |
邸斌, 李晓明, 尚耀东, 等. 影响下咽癌患者复发及其预后的临床病理学因素[J]. 中华耳鼻咽喉头颈外科杂志, 2009, 44(9): 716-721. DOI: 10.3760/cma.j.issn.1673-0860.2009.09.004.
doi: 10.3760/cma.j.issn.1673-0860.2009.09.004 |
[6] |
Tian S, Li Q, Li R, et al. Development and validation of a prognostic nomogram for hypopharyngeal carcinoma[J]. Front Oncol, 2021, 11(6): 696952. DOI: 10.3389/fonc.2021.696952.
doi: 10.3389/fonc.2021.696952 |
[7] |
Creak AL, Harrington K, Nutting C. Treatment of recurrent head and neck cancer: re-irradiation or chemotherapy?[J]. Clin Oncol (R Coll Radiol), 2005, 17(3): 138-147. DOI: 10.1016/j.clon.2004.10.008.
doi: 10.1016/j.clon.2004.10.008 |
[8] |
Fowler BZ, Muller S, Chen AY, et al. Factors influencing long-term survival following salvage total laryngectomy after initial radiotherapy or conservative surgery[J]. Head Neck, 2006, 28(2): 99-106. DOI: 10.1002/hed.20297.
doi: 10.1002/hed.20297 |
[9] |
Sewnaik A, Keereweer S, Al-Mamgani A, et al. High complication risk of salvage surgery after chemoradiation failures[J]. Acta Otolaryngol, 2012, 132(1): 96-100. DOI: 10.3109/00016489.2011.617779.
doi: 10.3109/00016489.2011.617779 |
[10] |
Putten L, Bree R, Doornaert PA, et al. Salvage surgery in post- chemoradiation laryngeal and hypopharyngeal carcinoma: outcome and review[J]. Acta Otorhinolaryngol Ital, 2015, 35(3): 162-172.
pmid: 26246660 |
[11] |
周凯, 梁乐平, 王延辉. 下咽癌患者的临床特征及其与预后的关系[J]. 癌症进展, 2020, 18(21): 2235-2237. DOI: 10.11877/j.issn.1672-1535.2020.18.21.20.
doi: 10.11877/j.issn.1672-1535.2020.18.21.20 |
[12] |
Tsetsos N, Poutoglidis A, Vlachtsis K, et al. Twenty-year experience with salvage total laryngectomy: lessons learned[J]. J Laryngol Otol, 2021, 135(8): 729-736. DOI: 10.1017/S0022215121001687.
doi: 10.1017/S0022215121001687 |
[13] |
Elbers JBW, Veldhuis LI, Bhairosing PA, et al. Salvage surgery for advanced stage head and neck squamous cell carcinoma following radiotherapy or chemoradiation[J]. Eur Arch Otorhinolaryngol, 2019, 276(3): 647-655. DOI: 10.1007/s00405-019-05292-0.
doi: 10.1007/s00405-019-05292-0 pmid: 30673847 |
[14] |
Akbaba S, Held T, Lang K, et al. Salvage radiotherapy for recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) after first-line treatment with surgery alone: a 10-year single-centre experience[J]. Radiat Oncol, 2019, 14(1): 34. DOI: 10.1186/s13014-019-1238-8.
doi: 10.1186/s13014-019-1238-8 pmid: 30782197 |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[4] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[5] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[6] | Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[7] | Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222. |
[8] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[9] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[10] | Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185. |
[11] | Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[12] | Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104. |
[13] | Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64. |
[14] | Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469. |
[15] | Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||